Ocular Inflammation and Pain - Pipeline Insight, 2021
This report can be delivered to the clients within 24 hours
DelveInsight’s, “Ocular Inflammation and Pain – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Ocular Inflammation and Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Ocular Inflammation and Pain: Overview
Inflammation is body’s response to injury, infection or irritation. In some cases, inflammation can occur in response to normally harmless substances, such as dust, grass or pollen. This is an allergic reaction. The immune system may also trigger inflammation in response to the body’s own tissues. This is called an autoimmune reaction. Eye inflammation occurs in response to infection, allergies, autoimmune disorders, irritation, or injury or trauma to the eye or eyelid. Symptoms of eye inflammation can affect the eyes, eyelids, or surrounding tissues and include: Blurry vision, Pain, Redness, Swelling, Tearing, Unusual warmth or heat. Ocular inflammation is also often present in patients with systemic inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, Wegener’s granulomatosis, Sjцgren’s syndrome, polyarteritis nodosa, primary antiphospholipid syndrome, Behзet’s syndrome, Kawasaki disease, Cogan’s syndrome, and relapsing polychondritis.
'Ocular Inflammation and Pain - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ocular Inflammation and Pain pipeline landscape is provided which includes the disease overview and Ocular Inflammation and Pain treatment guidelines. The assessment part of the report embraces, in depth Ocular Inflammation and Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ocular Inflammation and Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Ocular Inflammation and Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ocular Inflammation and Pain Emerging Drugs
Further product details are provided in the report……..
Ocular Inflammation and Pain: Therapeutic Assessment
This segment of the report provides insights about the different Ocular Inflammation and Pain drugs segregated based on following parameters that define the scope of the report, such as:
Ocular Inflammation and Pain: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ocular Inflammation and Pain therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ocular Inflammation and Pain drugs.
Ocular Inflammation and Pain Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Ocular Inflammation and Pain – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Ocular Inflammation and Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Ocular Inflammation and Pain: Overview
Inflammation is body’s response to injury, infection or irritation. In some cases, inflammation can occur in response to normally harmless substances, such as dust, grass or pollen. This is an allergic reaction. The immune system may also trigger inflammation in response to the body’s own tissues. This is called an autoimmune reaction. Eye inflammation occurs in response to infection, allergies, autoimmune disorders, irritation, or injury or trauma to the eye or eyelid. Symptoms of eye inflammation can affect the eyes, eyelids, or surrounding tissues and include: Blurry vision, Pain, Redness, Swelling, Tearing, Unusual warmth or heat. Ocular inflammation is also often present in patients with systemic inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, Wegener’s granulomatosis, Sjцgren’s syndrome, polyarteritis nodosa, primary antiphospholipid syndrome, Behзet’s syndrome, Kawasaki disease, Cogan’s syndrome, and relapsing polychondritis.
'Ocular Inflammation and Pain - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ocular Inflammation and Pain pipeline landscape is provided which includes the disease overview and Ocular Inflammation and Pain treatment guidelines. The assessment part of the report embraces, in depth Ocular Inflammation and Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ocular Inflammation and Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Ocular Inflammation and Pain R&D. The therapies under development are focused on novel approaches to treat/improve Ocular Inflammation and Pain.
This segment of the Ocular Inflammation and Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ocular Inflammation and Pain Emerging Drugs
- APP13007: Formosa pharmaceuticals
Further product details are provided in the report……..
Ocular Inflammation and Pain: Therapeutic Assessment
This segment of the report provides insights about the different Ocular Inflammation and Pain drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Ocular Inflammation and Pain
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Ocular Inflammation and Pain: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ocular Inflammation and Pain therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ocular Inflammation and Pain drugs.
Ocular Inflammation and Pain Report Insights
- Ocular Inflammation and Pain Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Ocular Inflammation and Pain drugs?
- How many Ocular Inflammation and Pain drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ocular Inflammation and Pain?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ocular Inflammation and Pain therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ocular Inflammation and Pain and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Ocular Inflammation and Pain: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
APP13007: Formosa pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
RX-10045: A.T. Resolve SARL
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I/II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Ocular Inflammation and Pain Key Companies
Ocular Inflammation and Pain Key Products
Ocular Inflammation and Pain- Unmet Needs
Ocular Inflammation and Pain- Market Drivers and Barriers
Ocular Inflammation and Pain- Future Perspectives and Conclusion
Ocular Inflammation and Pain Analyst Views
Ocular Inflammation and Pain Key Companies
Appendix
Executive Summary
Ocular Inflammation and Pain: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
APP13007: Formosa pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
RX-10045: A.T. Resolve SARL
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I/II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Ocular Inflammation and Pain Key Companies
Ocular Inflammation and Pain Key Products
Ocular Inflammation and Pain- Unmet Needs
Ocular Inflammation and Pain- Market Drivers and Barriers
Ocular Inflammation and Pain- Future Perspectives and Conclusion
Ocular Inflammation and Pain Analyst Views
Ocular Inflammation and Pain Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Ocular Inflammation and Pain
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Ocular Inflammation and Pain
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Ocular Inflammation and Pain
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Ocular Inflammation and Pain
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
